This technology is a recombinant fibroblast growth factor binding protein 1, FGFBP1, used to promote organoids survival and growth, with applications in drug discovery, regenerative medicine, and transplantation.
Organoids are three-dimensional tissue derived from stem cells that are widely used in drug screening, toxicology testing, and disease modeling, with emerging applications in transplantation. However, current organoid culture methods rely on costly growth media containing a limited set of established growth factors. Despite these factors, organoids often exhibit slow growth, poor survival following passaging, and drift away from the makeup of the native tissue over time. Similar challenges affect the preservation of donor tissue before transplant. There is a need for improved growth factors that support organoid grow, maintain native tissue characteristics, and enhance tissue preservation.
This technology is a recombinant fibroblast growth factor binding protein 1 (FGFBP1) that can boost the growth of organoids and gut tissue. FGFBP1 is a protein released by the stem cells that renew the intestinal lining, and the tissue cannot renew itself without it. When FGFBP1 is removed, intestinal cells stop dividing, the tissue fails to regenerate, and organoids cannot form. Adding recombinant FGFBP1 to organoid cultures does the opposite, improving their survival, growth, and expansion.
This technology has been validated in mouse models and in intestinal and colon organoids.
Patent Pending (WO/2025/217555)
IR CU24334
Licensing Contact: Jerry Kokoshka